Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2
subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients
with glomerulopathies